KRASG12C抑制剂IBI351单药治疗晚期非小细胞肺癌患者的疗效与安全性:2期关键研究结果
这项开放标签、单臂、2期关键研究纳入116例标准化疗失败且KRAS G12C突变的晚期非小细胞肺癌患者,口服IBI351 600 mg每日两次。独立影像评审委员会确认的客观缓解率为49.1%(95%CI 39.7-58.6),疾病控制率90.5%(95%CI 83.7-95.2),中位无进展生存期9.7个月(95%CI 5.6-11.0)。治疗相关不良事件发生率为92.2%,≥3级治疗相关不良事件为41.4%。
要点
- IBI351 600 mg每日两次单药在KRAS G12C突变晚期NSCLC中确认客观缓解率达49.1%。
- 中位无进展生存期为9.7个月,中位缓解持续时间未达到。
- ≥3级治疗相关不良事件发生率为41.4%,因不良事件停药者占7.8%。
核心结论
- IBI351单药显示出有前景且持久的疗效与可控的安全性,支持其作为KRAS G12C突变NSCLC潜在新治疗选择。
研究设计与样本
- 开放标签、单臂、2期关键研究,纳入标准化疗失败的KRAS G12C突变晚期NSCLC患者。
- IBI351口服给药,剂量为600 mg每日两次。
- 主要终点为独立影像评审委员会按RECIST v1.1评估的确认客观缓解率。
- 截至2023年12月13日,共纳入116例患者。
主要发现
- 患者中ECOG体能状态评分为1者占91.4%,脑转移者占30.2%,既往接受过抗PD-1或抗PD-L1抑制剂联合铂类化疗者占84.5%。
- 独立影像评审委员会确认的客观缓解率为49.1%(95%CI 39.7-58.6),疾病控制率为90.5%(95%CI 83.7-95.2)。
- 中位缓解持续时间未达到,发生疾病进展或死亡事件者22例(38.6%),中位无进展生存期为9.7个月(95%CI 5.6-11.0),总生存数据尚不成熟。
- 治疗相关不良事件发生于107例(92.2%),≥3级治疗相关不良事件发生于48例(41.4%),导致停药的治疗相关不良事件发生于9例(7.8%)。
- 常见治疗相关不良事件包括贫血(44.8%)、丙氨酸氨基转移酶升高(28.4%)、天冬氨酸氨基转移酶升高(27.6%)、乏力(26.7%)和尿蛋白阳性(25.0%)。
关键数值与推荐
- 在生物标志物可评估患者(n=95)中,所有患者组织KRAS G12C均为阳性,其中血液阳性72例、血液阴性23例。
- 组织和血液KRAS G12C均阳性者基线肿瘤负荷更高(p<0.05)且无进展生存期更差(p<0.05)。
- 与KRAS G12C共突变最常见的基因包括TP53(45.3%)、STK11(30.5%)和KEAP1(21.1%)。
- 在突变频率≥5%的13个基因中,STK11、KEAP1、PIK3CG、POLE、SMAD4和BRINP3六个基因的突变与更差的无进展生存期显著相关(p<0.05)。
- STK11突变与基线肿瘤负荷更高及缓解率更低显著相关(p<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: KRAS glycine-to-cysteine substitution at codon 12 (G12C) mutation is a well-recognized and increasingly promising therapeutic target with huge unmet clinical needs in NSCLC patients. IBI351 is a potent covalent and irreversible inhibitor of KRAS G12C. Here, we present the efficacy and safety of IBI351 from an open-label, single-arm, phase 2 pivotal study. METHODS: Eligible patients with NSCLC with KRAS G12C who failed standard therapy were enrolled. IBI351 was orally administered at a dose of 600 mg twice daily. The primary endpoint was confirmed objective response rate assessed by an independent radiological review committee (IRRC) as per Response Evaluation Criteria in Solid Tumors v1.1. Other endpoints were safety, IRRC-confirmed disease control rate, duration of response, progression-free survival (PFS), and overall survival. RESULTS: As of December 13, 2023, 116 patients were enrolled (Eastern Cooperative Oncology Group Performance Status 1: 91.4%; brain metastasis: 30.2%; prior treatments with both anti-PD-1 or anti-PD-L1 inhibitors and platinum-based chemotherapy: 84.5%). As per the IRRC assessment, the confirmed objective response rate was 49.1% (95% confidence interval [CI]: 39.7-58.6), and the disease control rate was 90.5% (95% CI: 83.7-95.2). The median duration of response was not reached whereas disease progression or death events occurred in 22 patients (38.6%), and the median PFS was 9.7 months (95% CI: 5.6-11.0). overall survival data was immature. Treatment-related adverse events (TRAEs) occurred in 107 patients (92.2%) whereas 48 patients (41.4%) had equal to or higher than grade three TRAEs. Common TRAEs were anemia (44.8%), increased alanine aminotransferase (28.4%), increased aspartate aminotransferase (27.6%), asthenia (26.7%) and presence of protein in urine (25.0%). TRAEs leading to treatment discontinuation occurred in nine patients (7.8%). In biomarker evaluable patients (n = 95), all patients had positive KRAS G12C in tissue whereas 72 patients were blood-positive and 23 were blood-negative for KRAS G12C. Patients with KRAS G12C in both blood and tissue had higher tumor burden at baseline (p < 0.05) and worse PFS (p < 0.05). Tumor mutation profiling identified tumor protein p53 (45.3%), serine/threonine kinase 11 (STK11) (30.5%), and kelch-like ECH-associated protein 1 (21.1%) as the most common genes co-mutated with KRAS G12C. Among 13 genes with mutation frequency equal to or higher than 5%, mutations of six genes (STK11, kelch-like ECH-associated protein 1, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma, DNA polymerase epsilon, SMAD family member 4, and BMP/retinoic acid-inducible neural-specific protein 3) were significantly associated with worse PFS (p < 0.05). Mutation in STK11 was also found to have a significant association with higher tumor burden at baseline and lower response rate (p < 0.05). CONCLUSIONS: IBI351 monotherapy demonstrated promising and sustained efficacy with manageable safety, supporting its potential as a new treatment option for KRAS G12C-mutant NSCLC.
引用
- Zhou Q, Meng X, Sun L, et al. Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study. J Thorac Oncol. 2024. PMID: 39127176. doi:10.1016/j.jtho.2024.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。